Pfizer's Updated COVID Shot Wins FDA Approval

Regulation
โดย GuruFocus·US·Read original
Summary · why it matters

Pfizer won FDA approval Thursday for its updated Comirnaty COVID vaccine, with deliveries starting immediately and doses expected in pharmacies and clinics within days. The vaccine, developed with BioNTech, is now limited to adults 65 and older and higher-risk patients aged 5 to 64, a much smaller market than the pandemic-era rollout. Comirnaty has distributed over five billion doses worldwide, but the new seasonal demand is uncertain. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine. Shares traded at $27.9079 on August 28, 5.27% above the GF Value estimate of $26.51, indicating a premium before uptake and reimbursement details emerge.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 4 stocks
Pfizer Inc
PFE
▲ PositiveRegulationrelevance

FDA approval allows Pfizer to start delivering its updated COVID vaccine.

BioNTech SE
22UA
▲ PositiveRegulationrelevance

BioNTech's partner vaccine gets FDA approval, enabling sales.

Moderna Inc
MRNA
▼ NegativeCompetitionrelevance

Pfizer's updated COVID shot approval intensifies competition for Moderna's vaccine.

Novavax Inc
NVAX
▼ NegativeCompetitionrelevance

Pfizer's approval adds competitive pressure to Novavax's COVID vaccine.

Health Care▼ · 1 stocks
Sanofi SA
SAN
▼ NegativeCompetitionrelevance

Pfizer's approval competes with Sanofi's protein-based COVID vaccine.

© 2026 MarketDXNews